Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vyleesi (bremelanotide) for the Treatment of Hypoactive Sexual Desire Disorder

Drug Name

Vyleesi™ (bremelanotide)

Developer

Palatin Technologies

Therapy Class

Peptide

Product Description

Melanocortin receptor agonist

Current Indication

Hypoactive sexual desire disorder

Market Sector

Women’s health

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top